Cooley advised SiteOne Therapeutics, a private biotechnology company developing small molecule inhibitors of sodium channels to treat pain and other neuronal hyperexcitability disorders, on its acquisition by Eli Lilly. Under the terms of the agreement, Eli Lilly will acquire SiteOne, and SiteOne shareholders could receive up to $1 billion in cash, inclusive of an upfront payment and subsequent payments upon achievement of certain regulatory and commercial milestones.
SiteOne Therapeutics to Be Acquired by Eli Lilly for up to $1 Billion